Why the study?
Does Schisandrin B prevent doxorubicin-induced chronic cardiotoxicity and enhance its anticancer activity in vivo?
Does Schisandrin B prevent doxorubicin-induced chronic cardiotoxicity and enhance its anticancer activity in vivo?
Schisandrin B is identified as a dual-action molecule that protects against doxorubicin-induced cardiotoxicity while enhancing its anticancer efficacy in vivo.
Hypothesis-generating in doxorubicin models; leaves open clinical translation of dual cardioprotection and efficacy.
Sch B is capable of protecting Dox-induced chronic cardiotoxicity and enhancing its anticancer activity. To the best of our knowledge, Sch B is the only molecule ever proved to function as a cardioprotective agent as well as a chemotherapeutic sensitizer, which is potentially applicable for cancer treatment.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: